SCHEMBL21812486

SCHEMBL21812486

OC1CN(c2cc(Br)ccn2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 1/20 0.45
▸ PROKR1 Q8TCW9 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ EGLN2 Q96KS0 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ LRRK2 Q5S007 2/20 0.34
▸ PDE10A Q9Y233 2/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HRH4 Q9H3N8 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ NCF1 P14598 1/20 0.32
▸ ITGB2 P05107 1/20 0.32
▸ ICAM1 P05362 1/20 0.32
▸ ITGAL P20701 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21333541 0.87 LRRK2 (0.44) ACACBPROKR1LRRK2PDE10AHRH4
SCHEMBL30438091 0.87 LRRK2 (0.44) ACACBPROKR1LRRK2PDE10AHRH4
SCHEMBL21345793 0.87 LRRK2 (0.44) ACACBPROKR1LRRK2PDE10AHRH4
SCHEMBL21333053 0.87 LRRK2 (0.44) ACACBPROKR1LRRK2PDE10AHRH4
SCHEMBL30438430 0.87 LRRK2 (0.44) ACACBPROKR1LRRK2PDE10AHRH4
SCHEMBL29083734 0.83 LRRK2 (0.42) ACACBLRRK2PIK3CAHRH4ITGB2
SCHEMBL29849995 0.82 HRH4 (0.44) ACACBKDM4EALDH1A1SMN1; SMN2HRH4
SCHEMBL13466911 0.79 PROKR1 (0.51) PROKR1KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL29741109 0.79 PROKR1 (0.42) PROKR1EGLN2LRRK2PDE10APIK3CA
SCHEMBL13280082 0.79 GRIN2D (0.49) PROKR1GRIN2BCDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 — — EP disclosed
US-12202816-B2 Compounds as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2025-01-21 — — US disclosed
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2022-02-03 — — US disclosed
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2022-02-03 — — US disclosed
EP-3856736-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2021-08-04 — — EP disclosed
CN-112930346-A Novel compounds as NADPH oxidase inhibitors 金其尤泰克斯瑞士股份有限公司 2021-06-08 — — CN disclosed
WO-2020065048-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2020-04-02 — — WO disclosed
EP-3628669-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2020-04-01 — — EP disclosed
EP-3628669-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2020-04-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202816-B2 Compounds as NADPH oxidase inhibitors CYBB, NOX1, NOX4 ACACB 360/4885PROKR1 4825/4885KDM4E 3830/4885
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CYBB, NOX1, NOX4 ACACB 325/4885PROKR1 4783/4885KDM4E 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback